Cucumber mosaic virus as drug delivery vehicle for doxorubicin

Biomaterials

Volumn 34, Issue 19, 2013, Pages 4632-4642

  Zeng, Qingbing ^a   Wen, Hanbin ^a   Wen, Qing ^a   Chen, Xiaohui ^a   Wang, Yuegang ^a   Xuan, Wanlin ^a   Liang, Jiansheng ^a   Wan, Shanhe ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Cucumber mosaic virus; Delivery vehicle; Doxorubicin; Ovarian cancer; Targeting

Indexed keywords

CUCUMBER MOSAIC VIRUS; DELIVERY VEHICLE; DOXORUBICIN; OVARIAN CANCERS; TARGETING;

CELL PROLIFERATION; DISEASES; ENZYME INHIBITION; MAMMALS; NANOCONJUGATES; ORGANIC ACIDS; PH; RNA; TRANSMISSION ELECTRON MICROSCOPY; VIRUSES;

RIGID STRUCTURES;

DOXORUBICIN; DRUG VEHICLE; FOLIC ACID;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER THERAPY; CARDIOMYOPATHY; CARDIOTOXICITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CUCUMBER MOSAIC VIRUS; CYTOTOXICITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG RELEASE; ENCAPSULATION; ENDOCYTOSIS; EOSINOPHILIA; FEMALE; GEL PERMEATION CHROMATOGRAPHY; HEART MUSCLE CELL; IN VITRO STUDY; INTERNALIZATION; MOUSE; NICK END LABELING; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; SEDIMENTATION RATE; TRANSMISSION ELECTRON MICROSCOPY; VIRUS MORPHOLOGY;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL LINE, TUMOR; CELLS, CULTURED; CUCUMOVIRUS; DELAYED-ACTION PREPARATIONS; DOXORUBICIN; DRUG DELIVERY SYSTEMS; FEMALE; FOLIC ACID; HUMANS; MICE; MICE, INBRED BALB C; MICE, NUDE; MODELS, MOLECULAR; MYOCYTES, CARDIAC; OVARIAN NEOPLASMS; OVARY;

CUCUMBER MOSAIC VIRUS; MIRIDAE; MUS MUSCULUS;

EID: 84875898519     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2013.03.017     Document Type: Article

References (61)

1. Minotti G., Menna P., Salvatorelli E., Cairo G., Gianni L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 2004, 56(2):185-229.
2. Ma Y., Nolte R.J.M., Cornelissen J.J.L.M. Virus-based nanocarriers for drug delivery. Adv Drug Deliv Rev 2012, 64(9):811-825.
3. Douglas T., Young M. Viruses: making friends with old foes. Science 2006, 312(5775):873-875.
4. Wang Q., Lin T., Tang L., Johnson J.E., Finn M.G. Icosahedral virus particles as addressable nanoscale building blocks. Angew Chem Int Ed 2002, 41(3):459-462.
5. Flenniken M.L., Liepold L.O., Crowley B.E., Willits D.A., Young M.J., Douglas T. Selective attachment and release of a chemotherapeutic agent from the interior of a protein cage architecture. Chem Commun 2005, 4:447-449.
6. Fiedler J.D., Brown S.D., Lau J.L., Finn M.G. RNA-directed packaging of enzymes within virus-like particles. Angew Chem Int Ed 2010, 49(50):9648-9651.
7. Zeng Q., Li T., Cash B., Li S., Xie F., Wang Q. Chemoselective derivatization of a bionanoparticle by click reaction and ATRP reaction. Chem Commun 2007, 14:1453-1455.
8. Zeng Q., Saha S., Lee L.A., Barnhill H., Oxsher J., Dreher T., et al. Chemoselective modification of turnip yellow mosaic virus by Cu (I) catalyzed azide-alkyne 1,3-dipolar cycloaddition reaction and its application in cell binding. Bioconjug Chem 2011, 22(1):58-66.
9. Kaur G., Valarmathi M.T., Potts J.D., Wang Q. The promotion of osteoblastic differentiation of rat bone marrow stromal cells by a polyvalent plant mosaic virus. Biomaterials 2008, 29(30):4074-4081.
10. Barnhill H.N., Claudel-Gillet S., Ziessel R., Charbonnière L.J., Wang Q. Prototype protein assembly as scaffold for time-resolved fluoroimmuno assays. J Am Chem Soc 2007, 129(25):7799-7806.
11. Manchester M., Singh P. Virus-based nanoparticles (VNPs): platform technologies for diagnostic imaging. Adv Drug Deliv Rev 2006, 58(14):1505-1522.
12. Zan X., Sitasuwan P., Powell J., Dreher T.W., Wang Q. Polyvalent display of RGD motifs on turnip yellow mosaic virus for enhanced stem cell adhesion and spreading. Acta Biomater 2012, 8(8):2978-7985.
13. Kaiser C.R., Flenniken M.L., Gillitzer E., Harmsen A.L., Harmsen A.G., Jutila M.A., et al. Biodistribution studies of protein cage nanoparticles demonstrate broad tissue distribution and rapid clearance in vivo. Int J Nanomed 2007, 2(4):715.
14. Destito G., Yeh R., Rae C.S., Finn M.G., Manchester M. Folic acid-mediated targeting of cowpea mosaic virus particles to tumor cells. Chem Biol 2007, 14(10):1152-1162.
15. Singh P., Prasuhn D., Yeh R.M., Destito G., Rae C.S., Osborn K., et al. Bio-distribution, toxicity and pathology of cowpea mosaic virus nanoparticles in vivo. J Control Release 2007, 120(1):41-50.
16. Allen M., Bulte J., Liepold L., Basu G., Zywicke H.A., Frank J.A., et al. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med 2005, 54(4):807-812.
17. Uchida M., Flenniken M.L., Allen M., Willits D.A., Crowley B.E., Brumfield S., et al. Targeting of cancer cells with ferrimagnetic ferritin cage nanoparticles. J Am Chem Soc 2006, 128(51):16626-16633.
18. Suthiwangcharoen N., Li T., Li K., Thompson P., You S., Wang Q. M13 bacteriophage-polymer nanoassemblies as drug delivery vehicles. Nano Res 2011, 4(5):483-493.
19. Wu W., Hsiao S.C., Carrico Z.M., Francis M.B. Genome-free viral capsids as multivalent carriers for taxol delivery. Angew Chem Int Ed 2009, 48(50):9493-9497.
20. Lockney D.M., Guenther R.N., Loo L., Overton W., Antonelli R., Clark J., et al. The red clover necrotic mosaic virus capsid as a multifunctional cell targeting plant viral nanoparticle. Bioconjug Chem 2010, 22(1):67-73.
21. Sgro J.Y. Virus taxonomy: eighth report of the international committee on taxonomy of viruses 2005, 1162. Academic Press. 2nd ed. C.M. Fauquet (Ed.).
22. Palukaitis P., Roossinck M.J., Dietzgen R.G., Francki R.I.B. Cucumber mosaic virus. Adv Virus Res 1992, 41:281-348.
23. Wikoff W.R., Tsai C.J., Wang G., Baker T.S., Johnson J.E. The structure of cucumber mosaic virus: cryoelectron microscopy, X-ray crystallography, and sequence analysis. Virology 1997, 232(1):91-97.
24. Smith T.J., Chase E., Schmidt T., Perry K.L. The structure of cucumber mosaic virus and comparison to cowpea chlorotic mottle virus. J Virol 2000, 74(16):7578-7586.
25. Canal F., Vicent M.J., Pasut G., Schiavon O. Relevance of folic acid/polymer ratio in targeted PEG-epirubicin conjugates. J Control Release 2010, 146(3):388-399.
26. Gao X., Cui Y., Levenson R.M., Chung L.W.K., Nie S. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat Biotechnol 2004, 22(8):969-976.
27. Qian X., Peng X.H., Ansari D.O., Yin-Goen Q., Chen G.Z., Shin D.M., et al. In vivo tumor targeting and spectroscopic detection with surface-enhanced Raman nanoparticle tags. Nat Biotechnol 2007, 26(1):83-90.
28. Scott H. Purification of cucumber mosaic virus. Virology 1963, 20(1):103-106.
29. Perry K.L., Zhang L., Palukaitis P. Amino acid changes in the coat protein of cucumber mosaic virus differentially affect transmission by the aphids Myzus persicae and Aphis gossypii. Virology 1998, 242(1):204-210.
30. Peden K. Cucumber mosaic virus contains a functionally divided genome. Virology 1973, 53:487-492.
31. Palukaitis P., Zaitlin M. Satellite RNAs of cucumber mosaic virus: characterization of two new satellites. Virology 1984, 132(2):426-435.
32. Rao A., Francki R. Comparative studies on tomato aspermy and cucumber mosaic viruses. VI. Partial compatibility of genome segments from the two viruses. Virology 1981, 114(2):573-575.
33. Dreher M.R., Raucher D., Balu N., Michael Colvin O., Ludeman S.M., Chilkoti A. Evaluation of an elastin-like polypeptide-doxorubicin conjugate for cancer therapy. J Control Release 2003, 91(1):31-43.
34. Willner D., Trail P.A., Hofstead S.J., King H.D., Lasch S.J., Braslawsky G.R., et al. (6-Maleimidocaproyl) hydrazone of doxorubicin. A new derivative for the preparation of immunoconjugates of doxorubicin. Bioconjug Chem 1993, 4(6):521-527.
35. Liu S.Q., Tong Y.W., Yang Y.Y. Incorporation and in vitro release of doxorubicin in thermally sensitive micelles made from poly (N-isopropylacrylamide-co-N,N-dimethylacrylamide)-b-poly (d, l-lactide-co-glycolide) with varying compositions. Biomaterials 2005, 26(24):5064.
36. 2 toxicity. Am J Physiol-Heart C 1999, 276(1):H167-H175.
37. Bareford L.M., Swaan P.W. Endocytic mechanisms for targeted drug delivery. Adv Drug Deliv Rev 2007, 59(8):748-758.
38. Nicolay K., Timmers R.J.M., Spoelstra E., Van der Neut R., Fok J.J., Huigen Y.M., et al. The interaction of adriamycin with cardiolipin in model and rat liver mitochondrial membranes. Biochim Biophys Acta Biomembr 1984, 778(2):359-371.
39. Simpkins H., Pearlman L.F., Thompson L.M. Effects of adriamycin on supercoiled DNA and calf thymus nucleosomes studied with fluorescent probes. Cancer Res 1984, 44(2):613-618.
40. Missirlis D., Kawamura R., Tirelli N., Hubbell J.A. Doxorubicin encapsulation and diffusional release from stable, polymeric, hydrogel nanoparticles. Eur J Pharm Sci 2006, 29(2):120-129.
41. Porumb H. The solution spectroscopy of drugs and the drug-nucleic acid interactions. Prog Biophys Mol Biol 1978, 34(3):175.
42. de Wolf F.A., Maliepaard M., van Dorsten F., Berghuis I., Nicolay K., de Kruijff B. Comparable interaction of doxorubicin with various acidic phospholipids results in changes of lipid order and dynamics. Biochim Biophys Acta Mol Basis Dis 1990, 1096(1):67-80.
43. Li K., Chen Y., Li S., Nguyen H.G., Niu Z., You S., et al. Chemical modification of M13 bacteriophage and its application in cancer cell imaging. Bioconjug Chem 2010, 21(7):1369-1377.
44. Husain N., Agbaria R.A., Warner I.M. Spectroscopic analysis of the binding of doxorubicin to human. alpha,-1 acid glycoprotein. J Phys Chem 1993, 97(41):10857-10861.
45. Chaires J.B., Dattagupta N., Crothers D.M. Self-association of daunomycin. Biochemistry-US 1982, 21(17):3927-3932.
46. Barry E., Alvarez J.A., Scully R.E., Miller T.L., Lipshultz S.E. Anthracycline-induced cardiotoxicity: course, pathophysiology, prevention and management. Expert Opin Pharmacol 2007, 8(8):1039-1058.
47. Chen B., Peng X., Pentassuglia L., Lim C.C., Sawyer D.B. Molecular and cellular mechanisms of anthracycline cardiotoxicity. Cardiovasc Toxicol 2007, 7(2):114-121.
48. Gianni L., Herman E.H., Lipshultz S.E., Minotti G., Sarvazyan N., Sawyer D.B. Anthracycline cardiotoxicity: from bench to bedside. J Clin Oncol 2008, 26(22):3777-3784.
49. Boucek R.J., Miracle A., Anderson M., Engelman R., Atkinson J., Dodd D.A. Persistent effects of doxorubicin on cardiac gene expression. J Mol Cell Cardiol 1999, 31(8):1435-1446.
50. Peng X., Chen B., Lim C.C., Sawyer D.B. The cardiotoxicology of anthracycline chemotherapeutics: translating molecular mechanism into preventative medicine. Mol Interv 2005, 5(3):163-171.
51. Simunek T., Sterba M., Popelová O., Adamcová M., Hrdina R., Gersl V. Anthracycline-induced cardiotoxicity: overview of studies examining the roles of oxidative stress and free cellular iron. Pharmacol Rep 2009, 61(1):154-171.
52. Sharma A., Sharma U.S. Liposomes in drug delivery: progress and limitations. Int J Pharm 1997, 154(2):123-140.
53. Zhang H., Liu Y., Yao D., Yang B. Hybridization of inorganic nanoparticles and polymers to create regular and reversible self-assembly architectures. Chem Soc Rev 2012, 41(18):6066-6088.
54. Plocova D., Etrych T., Ulbrich K., ř́hová B. HPMA-hydrogels result in prolonged delivery of anticancer drugs and are a promising tool for the treatment of sensitive and multidrug resistant leukaemia. Eur J Cancer 2002, 38(4):602-608.
55. Zaloudek Charles F. Tumor of the female genital tract; part A. Ovary, fallopian tube and broad and round ligaments. Diagnostic histopathology of tumors 2007, Churchill Livingstone, [chapter 13]. C.D.M. Fletcher (Ed.).
56. Ye B., Skates S., Mok S.C., Horick N.K., Rosenberg H.F., Vitonis A., et al. Proteomic-based discovery and characterization of glycosylated eosinophil-derived neurotoxin and COOH-terminal osteopontin fragments for ovarian cancer in urine. Clin Cancer Res 2006, 12(2):432-441.
57. Schleich H.G., Wiest W., Schmidt R., Hofmann I., Altenburg H.P., Melchert F. Ovarian carcinoma: increase in clinical validity by simultaneous determination of SRA and CA 125. J Cancer Res Clin 1987, 113(6):603-607.
58. Rosenberg H.F. The eosinophil ribonucleases. Cell Mol Life Sci 1998, 54(8):795-803.
59. Samoszuk M., Lin F., Rim P., Strathearn G. New marker for blood vessels in human ovarian and endometrial cancers. Clin Cancer Res 1996, 2(11):1867-1871.
60. Schwartz R.S. The hypereosinophilic syndrome and the biology of cancer. N Engl J Med 2003, 348(13):1199-1200.
61. Samoszuk M. Eosinophils and human cancer. Histol Histopathol 1997, 12:807-812.